Latest news with #pharmaservices
Yahoo
2 days ago
- Business
- Yahoo
Biovica Secures Three New Work Orders in Pharma Services of 2,5 MSEK in Value
UPPSALA, SE / / June 10, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a leader in blood-based cancer monitoring, has signed three new work orders within its Pharma Services business, with a combined value of approximately SEK 2.5 million. The agreements are for TKa testing services with existing customers. Two of the three work orders were placed by the Tier-1 (revenues >10 BUSD) U.S. pharmaceutical company which recently entered into a broader service agreement with Biovica, including a record-breaking SEK 4 million work order. These latest orders will support the development of next-generation CDK4/6 inhibitors. The orders are a combination of retrospective analysis, that will be performed in the coming months, and prospective analysis that will be performed over ~2 years. "I'm pleased to see that our Pharma customers recognize the value of DiviTum® TKa and are returning for continued use. The reliable and meaningful data it provides continues to drive demand from leading pharmaceutical companies, who use it in the development of new cancer therapies that will benefit patients.," said Anders Rylander, CEO of Biovica. Contact Anders Rylander, CEOPhone: +46 76 666 16 47E-mail: Anders Morén, CFOPhone: +46 73 125 92 46E-mail: Biovica - Treatment decisions with greater confidence Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: Attachments Biovica secures three new work orders in Pharma Services of 2,5 MSEK in value SOURCE: Biovica International View the original press release on ACCESS Newswire
Associated Press
12-05-2025
- Business
- Associated Press
The Lockwood Group Welcomes IDEOlogy Health - Accelerating its Leadership Role in Community Oncology
STAMFORD, Conn., May 12, 2025 /PRNewswire/ -- The Lockwood Group, a global pharma services organization, announced today the acquisition of IDEOlogy Health, based in Austin, TX, a best-in-class omnichannel medical education company known for its innovative engagement platforms and strategic healthcare provider communications tools. The acquisition strengthens The Lockwood Group's commitment to delivering data-driven, high-impact medical strategy and communications for life science companies worldwide. This strategic move combines The Lockwood Group's deep scientific expertise and integrated services with IDEOlogy Health's proprietary non-promotional educational solutions and strong reputation in oncology and hematology—including exclusive community oncology partnerships. Together, the unified organization will offer clients expanded capabilities, enhanced digital engagement tools, and greater scale across all facets of medical communications. 'We are thrilled to welcome IDEOlogy Health to the Lockwood team,' said Matthew Schecter, Founder & CEO of The Lockwood Group. 'Their culture of innovation, scientific rigor, and unique engagement tools are a perfect complement to our strategic vision. This partnership accelerates our ability to offer differentiated value to our clients and deepens our impact on healthcare providers and, ultimately, patients. We look forward to working alongside Mike Gramling (founder IDEOlogy Health), Cameron Lush, PhD (President), and their team as they continue to execute on their vision while leveraging The Lockwood Group's strong operational success and history' The integration of IDEOlogy Health's technology platforms—including IDEO Talks and Sound Bites—into The Lockwood Group's offering will enable more personalized, data-driven engagement strategies for clients navigating increasingly complex therapeutic landscapes. Additionally, this acquisition positions The Lockwood Group for continued growth in the oncology and rare disease sectors. 'This is an exciting new chapter for IDEOlogy Health,' said Mike Gramling, 'Joining forces with The Lockwood Group allows us to scale our impact, expand our reach, and elevate the work we do with our clients and our partners in community oncology. Together, we're poised to redefine what excellence in medical communications looks like.' Jefferies acted as exclusive financial advisor to IDEOlogy Health. About The Lockwood Group The Lockwood Group is a global pharma services organization with over 600 employees, that partners with pharmaceutical and biotechnology companies to translate complex science into compelling strategies that drive clinical and commercial success. Learn more at About IDEOlogy Health IDEOlogy Health's unique strategic collaborations with leading community oncology partners allow them to build customized multichannel medical communications that are unique to their networks. Additionally, IDEOlogy Health is host to multiple congresses including the CME-accredited Texas Lung Cancer Conference, World Conference on Genitourinary Cancers, and the Nashville Hematology Conference. IDEOlogy Health's platforms are known for driving measurable impact in specialty medicine. Learn more at CONTACTS: The Lockwood Group [email protected] 203-883-8747 View original content to download multimedia: SOURCE The Lockwood Group
